Wednesday, June 26, 2019 Daily Archives

Taking Your Molecule Through Process Validation

by and

The dynamics of the biopharmaceutical industry to get innovative products to the client has evolved over the years. Studies have shown that by 2021, biologics and biosimilar products are projected to have higher growth than other pharmaceutical products. Following the industry trend, Avid Bioservices as a Contract Development Manufacturing Organization (CDMO) has helped numerous clients complete their process validations campaigns. Between 2016 to 2019, Avid has successfully completed six. This custom report will share some key factors to consider for…

June 26, 2019

Cobra’s Symbiosis relationship making UK cell and gene competitive

by

CDMOs Cobra Biologics and Symbiosis have completed a collaboration they say has increased and simplified viral vector production and increased the UK’s competitiveness in cell and gene therapy services. After 18 months, the £4.8 million ($6 million) project has come to an end. The collaboration intended to build up viral vector capabilities while supporting the development of gene therapies in the UK, and the two contract development and manufacturing organizations (CDMOs) say these aims have been achieved. “One key aim…

June 26, 2019

WuXi invests in ADCs again to prep for commercial products

by

WuXi Biologics will further expand an antibody-drug conjugate (ADC) facility in China on the expectation of its clients’ projects moving to commercial production. In June 2018, WuXi Biologics announced plans to construct a $20 million (€17.6 million), 6,000 square meter facility for protein conjugates, including ADCs, set to be operational later this year. A year on, and the Chinese contract development and manufacturing organization (CDMO) has said it is further expanding the site in Wuxi city, China adding cGMP commercial…

June 26, 2019

$63bn Allergan deal: ‘Humira is buying the assets that will replace it’

by

The acquisition of Allergan will bring AbbVie’s growth platform to critical mass as revenues from lead biologic Humira (adalimumab) feel the heat from biosimilar competition. What is expected to become the second largest megamerger in the pharma space was announced yesterday, with AbbVie entering into a $63 billion (€55 billion) agreement to buy Allergan. (The largest deal is Bristol-Myers Squibb’s proposed $74 billion megamerger with Celgene, announced in January.) The merger will bring AbbVie numerous assets in the neuroscience, medical…

June 26, 2019